Evaluation of cisplatin + 5-Fu, carboplatin + 5-Fu, and ifosfamide + epirubicine regimens using the micronuclei test and nuclear abnormalities in the buccal mucosaTORRES-BUGARIN, O; VENTURA-AGUILAR, A; ZAMORA-PEREZ, A et al.Mutation research. Genetic toxicology and environmental mutagenesis. 2003, Vol 539, Num 1-2, pp 177-186, issn 1383-5718, 10 p.Article

Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic ExposureSCHMITT, Antonin; GLADIEFF, Laurence; PINGUET, Frédéric et al.Journal of clinical oncology. 2010, Vol 28, Num 30, pp 4568-4574, issn 0732-183X, 7 p.Article

A note on the solution chemistry of carboplatin in aqueous solutionsLEDERER, M; LEIPZIG-PAGANI, E.International journal of pharmaceutics. 1998, Vol 167, Num 1-2, pp 223-228, issn 0378-5173Article

Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivityMARKMAN, Maurie; ZANOTTI, Kristine; PETERSON, Gertrude et al.Journal of clinical oncology. 2003, Vol 21, Num 24, pp 4611-4614, issn 0732-183X, 4 p.Article

Flat dosing of carboplatin is justified in adult patients with normal renal functionEKHART, Corine; DE JONGE, Milly E; HUITEMA, Alwin D. R et al.Clinical cancer research. 2006, Vol 12, Num 21, pp 6502-6508, issn 1078-0432, 7 p.Article

Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumoursWHELAN, Jeremy S; MCTIERNAN, Anne; KAKOURI, Eleni et al.Pediatric blood & cancer. 2004, Vol 43, Num 3, pp 237-242, issn 1545-5009, 6 p.Article

Dix ans de carboplatinePUJADE-LAURAINE, Eric; ARMAND, Jean-Pierre.Bulletin du cancer. 2000, Vol 87, Num AOU, issn 0007-4551, 53 p., NSSerial Issue

Individualisation de dose du carboplatine en chimiothérapie = Dose individualisation for carboplatin in cancer chemotherapyOUDARD, S; PUJADE LAURAINE, E.Bulletin du cancer. 1997, Vol 84, Num 6, pp 675-677, issn 0007-4551Article

Mechanisms of resistance to cisplatin and carboplatinSTEWART, David J.Critical reviews in oncology/hematology. 2007, Vol 63, Num 1, pp 12-31, issn 1040-8428, 20 p.Article

Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumorsSCOPECE, Luciano; FRANCESCHI, Enrico; CRINO, Lucio et al.Journal of neuro-oncology. 2006, Vol 79, Num 3, pp 299-305, issn 0167-594X, 7 p.Article

Successful carboplatin desensitization in patients with proven carboplatin allergyCONFINO-COHEN, Ronit; FISHMAN, Amiram; ALTARAS, Marco et al.Cancer. 2005, Vol 104, Num 3, pp 640-643, issn 0008-543X, 4 p.Article

Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumorsEDELMAN, Martin J; BAUER, Kenneth S; SUHLAN WU et al.Clinical cancer research. 2007, Vol 13, Num 9, pp 2667-2674, issn 1078-0432, 8 p.Article

Phase I trial of combretastatin A-4 phosphate with carboplatinBILENKER, Joshua H; FLAHERTY, Keith T; SCHNALL, Mitchell et al.Clinical cancer research. 2005, Vol 11, Num 4, pp 1527-1533, issn 1078-0432, 7 p.Article

Validation of the limited-sampling models for carboplatin AUC in combination chemotherapy with taxanesMIYAZAKI, Mitsuru; OGURI, Tetsuya; KURATA, Takayasu et al.Anticancer research. 2004, Vol 24, Num 3B, pp 1911-1914, issn 0250-7005, 4 p.Article

Validation of high-performance liquid chromatographic assay methods for the analysis of carboplatin in plasma ultrafiltrateBURNS, R. B; EMBREE, L.Journal of chromatography. B, Biomedical sciences and applications. 2000, Vol 744, Num 2, pp 367-376, issn 1387-2273Article

Calvert's formula for dosing carboplatin: Overview and concerns of applicability in high-dose settingMAZUMDAR, Madhu; SMITH, Alex; TONG, William P et al.Journal of the National Cancer Institute. 2000, Vol 92, Num 17, pp 1434-1436, issn 0027-8874Article

Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum ComplexesHALL, Matthew D; TELMA, Katherine A; CHANG, Ki-Eun et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 14, pp 3913-3922, issn 0008-5472, 10 p.Article

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatinEKHART, Corine; RODENHUIS, Sjoerd; SMITS, Paul H. M et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 11, pp 1009-1015, issn 1744-6872, 7 p.Article

Thermothérapie et thermochimiothérapie au laser diode dans le traitement du rétinoblastome = Diode laser thermotherapy and chemothermotherapy in the treatment of retinoblastomaLUMBROSO, L; DOZ, F; LEVY, C et al.Journal français d'ophtalmologie. 2003, Vol 26, Num 2, pp 154-159, issn 0181-5512, 6 p.Article

High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplantCOLBY, C; KOZIOL, S; MCAFEE, S. L et al.Bone marrow transplantation (Basingstoke). 2002, Vol 29, Num 6, pp 467-472, issn 0268-3369Article

A Randomized Comparison of Platinum Chromium-Based Everolimus-Eluting Stents Versus Cobalt Chromium-Based Zotarolimus-Eluting Stents in All-Comers Receiving Percutaneous Coronary InterventionKYUNG WOO PARK; KANG, Si-Hyuck; JEONG, Myung-Ho et al.Journal of the American College of Cardiology. 2014, Vol 63, Num 25, pp 2805-2816, issn 0735-1097, 12 p., aArticle

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphomaFELDMAN, Tatyana; MATO, Anthony R; VALENTINETTI, Marisa et al.British journal of haematology. 2014, Vol 166, Num 1, pp 77-83, issn 0007-1048, 7 p.Article

Carboplatin-containing regimens as front-line treatment for advanced non-small-cell lung cancer in two groups of elderlyGIULIANI, Jacopo; PIACENTINI, Paolo; GRECO, Filippo et al.Journal of chemotherapy (Testo stampato). 2014, Vol 26, Num 2, pp 111-116, issn 1120-009X, 6 p.Article

Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancerKOUSSOUNADIS, A; LANGDON, S. P; HARRISON, D. J et al.British journal of cancer. 2014, Vol 110, Num 12, pp 2975-2984, issn 0007-0920, 10 p.Article

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)JOERGER, M; BATY, F; ROTHSCHILD, S et al.Lung cancer. 2014, Vol 85, Num 2, pp 306-313, issn 0169-5002, 8 p.Article